# OnCo record nct01824875 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct01824875/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct01824875", "NCT01824875" ;
  schema:name "ECOG-ACRIN E2211"@en ;
  schema:alternateName "E2211"@en ;
  schema:description "The randomised trial behind CAPTEM: adding capecitabine to temozolomide lengthened the time before pancreatic neuroendocrine tumours grew."@en ;
  schema:url <https://onco.cc/trials/nct01824875/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01824875>, <https://doi.org/10.1200/JCO.22.01013> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/pancreatic-net/> ;
  onco:drugs <https://onco.cc/drugs/capecitabine-temozolomide/>, <https://onco.cc/drugs/temozolomide/> ;
  onco:companies <https://onco.cc/companies/ecog-acrin/> .